A Review of New Fluoroquinolones

@article{Zhanel2006ARO,
  title={A Review of New Fluoroquinolones},
  author={George G. Zhanel and Sonya Fontaine and Heather J. Adam and Kristen N. Schurek and Matt Mayer and Ayman Noreddin and Alfred S. Gin and Ethan Rubinstein and Daryl J. Hoban},
  journal={Treatments in Respiratory Medicine},
  year={2006},
  volume={5},
  pages={437-465}
}
The new respiratory fluoroquinolones (gatifloxacin, gemifloxacin, levofloxacin, moxifloxacin, and on the horizon, garenoxacin) offer many improved qualities over older agents such as ciprofloxacin. These include retaining excellent activity against Gram-negative bacilli, with improved Gram-positive activity (including Streptococcus pneumoniae and Staphylococcus aureus). In addition, gatifloxacin, moxifloxacin and garenoxacin all demonstrate increased anaerobic activity (including activity… Expand
Levofloxacin : a review of its use as a high-dose, short-course treatment for bacterial infection.
TLDR
Levofloxacin is a valuable antimicrobial agent that has activity against a wide range of bacterial pathogens; however, its use should be considered carefully so that the potential for resistance selection can be minimized and its usefulness in severe infections and against a range of penicillin- and macrolide-resistant pathogens can be maintained. Expand
Clinical Role of an Injectable New Quinolone Antibiotic , Pazufloxacine Mesilate
Pazufloxacin mesilate (PZFX) is an injectable new-quinolone antibiotic having 1-amino cyclo propyl group. It has been seen in basic studies that PZFX shows high blood concentration after intravenousExpand
Comparative pharmacodynamics of garenoxacin, gemifloxacin, and moxifloxacin in community-acquired pneumonia caused by Streptococcus pneumoniae: a Monte Carlo simulation analysis.
OBJECTIVE This study used Monte Carlo simulations to assess the potential for attainment of pharmacodynamic targets with the fluoroquinolones garenoxacin, gemifloxacin, and moxifloxacin againstExpand
Chapter 4 – Gemifloxacin
A comprehensive profile on Gemifloxacin, a novel fluoroquinolone synthetic broad-spectrum antibacterial agent for oral administration, particularly indicated for treatment of community-acquiredExpand
Multidrug-Resistant Streptococcus pneumoniae Infections
TLDR
The so-called respiratory fluoroquinolones offer the advantages of easy administration and a spectrum covering extracellular and intracellular pathogens, however, their broad spectrum raises questions regarding the global risk of resistance selection and their safety profile is far from optimal for wide use in the community. Expand
New antimicrobial molecules and new antibiotic strategies.
TLDR
Few new agents have reached the market in the last decade with potential interest for community-acquired pneumonia (CAP) treatment, including linezolid (the first oxazolidinone in clinical use), new fluoroquinolones, cefditoren, ertapenem, and telithromycin. Expand
Macrolide Resistance in Cases of Community-Acquired Bacterial Pneumonia in the Emergency Department.
TLDR
This review considers macrolide use for CAP in the emergency department by reviewing the microbiologic environment in the United States and whether macrolides can overcome in vitro resistance during actual clinical use and no definitive answer is available on whetherMacrolides will achieve treatment success despite infection with in  vitro resistant strains. Expand
Review of moxifloxacin hydrochloride ophthalmic solution in the treatment of bacterial eye infections
TLDR
Vigamox is a bactericidal, concentration dependent, anti-infective, preservative free, and well tolerated with minimal ocular side effects and provides increased penetration into ocular tissues and fluids with improved activity against Streptococci and Staphylococci species. Expand
Use of microdialysis for the assessment of fluoroquinolone pharmacokinetics in the clinical practice
TLDR
Tissue concentrations need to be interpreted within the context of the pathogenesis and causative agents implicated in infections and integration of microdialysis ‐derived tissue pharmacokinetics with pharmacodynamic data offers crucial information for correlating exposure with antibacterial effect. Expand
Cardiac events after macrolides or fluoroquinolones in patients hospitalized for community-acquired pneumonia: post-hoc analysis of a cluster-randomized trial
TLDR
Among patients with CAP hospitalized to non-ICU wards, erythromycin use was associated with a 68% increased risk of hospital-acquired cardiac events, mainly heart failure. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 244 REFERENCES
A Critical Review of the Fluoroquinolones
TLDR
The new fluoroquinolones offer several advantages over ciprofloxacin and are emerging as important therapeutic agents in the treatment of community-acquired respiratory infections, and may be used orally in place of intravenous antibacterials. Expand
Gatifloxacin, gemifloxacin, and moxifloxacin: the role of 3 newer fluoroquinolones.
  • L. Saravolatz, J. Leggett
  • Medicine
  • Clinical infectious diseases : an official publication of the Infectious Diseases Society of America
  • 2003
TLDR
These agents can be useful for treatment of bacterial respiratory tract infections in patients who are allergic to beta-lactams, but caution must be exercised to avoid the potential for selection of widespread resistance, which may occur with indiscriminate use. Expand
Gemifloxacin: a new, potent fluoroquinolone for the therapy of lower respiratory tract infections
TLDR
Gemifloxacin is the most potent antimicrobial agent in vitro for S. pneumoniae, and has excellent activity against the other key pathogens of acute bacterial exacerbations of chronic bronchitis and community acquired pneumonia, including the atypical microorganisms. Expand
Pharmacokinetics and pharmacodynamics of the new fluoroquinolones: focus on respiratory infections.
TLDR
The new fluoroquinolones display excellent pharmacokinetic and pharmacodynamic properties against community-acquired respiratory pathogens, making them ideal agents for the empirical treatment of community- Acquired respiratory infections. Expand
In vitro activity of gatifloxacin, a new fluoroquinolone, against 204 anaerobes compared to seven other compounds.
TLDR
The broad in vitro spectrum of gatifloxacin is promising for the treatment of mixed anaerobic infections, especially those of the respiratory tract, ear, sinus, skin and soft tissues, and bite wounds. Expand
Gatifloxacin, an Advanced 8‐Methoxy Fluoroquinolone
Gatifloxacin is a new 8—methoxy‐fluoroquinolone antibiotic approved for use in the United States in December 1999. It has a broad spectrum of activity with potent activity against gram‐positiveExpand
The new fluoroquinolones: A critical review.
  • G. Zhanel, A. Walkty, +4 authors D. Hoban
  • Medicine
  • The Canadian journal of infectious diseases = Journal canadien des maladies infectieuses
  • 1999
TLDR
The new fluoroquinolones have the potential to emerge as important therapeutic agents in the treatment of respiratory tract and genitourinary tract infections and may result in savings in situations where they can be used orally in place of intravenous antibiotics. Expand
Gemifloxacin: A New Fluoroquinolone Approved for Treatment of Respiratory Infections
TLDR
Gemifloxacin may be a suitable choice for empiric treatment of CAP or AECB, however, due to the significant history of fluoroquinolone-induced hepatic failure and dermatologic complications, the use of this drug should be closely monitored. Expand
In Vitro Antibacterial Activity and Pharmacodynamics of New Quinolones
TLDR
Drugs with the most favourable pharmacokinetic/pharmacodynamic characteristics should be used as first-line agents in order to preserve the potential of this drug class and, most importantly, to provide the patient with an optimally effective regimen. Expand
Sparfloxacin. A review of its antibacterial activity, pharmacokinetic properties, clinical efficacy and tolerability in lower respiratory tract infections.
TLDR
The good activity of sparfloxacin against S. pneumoniae and other respiratory pathogens supports its use in lower respiratory tract infections, particularly community-acquired pneumonia. Expand
...
1
2
3
4
5
...